NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

RecruitingN/A

Sponsor: AstraZeneca

Conditions: ATTR Amyloidosis

Interventions: no intervention

Countries: United States, Canada, China, Denmark, Germany, Italy, Japan, Portugal

The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients aged \>18 years at study index date AND
* A reported diagnosis code for amyloidosis OR
* A claim for ATTR-specific treatment OR
* A positive biopsy for amyloidosis and positive immunostaining result of biopsy for ATTR

Exclusion Criteria:

* Evidence of primary (AL) and secondary (AA) amyloidosis AND/OR
* At least one claim/procedure code for stem cell transplant or at least two claims/procedure codes for chemotherapy and autoimmune disease drugs which may represent AL (primary) or AA (secondary) amyloidosis treatments

Locations (29)

Eden Prairie, Minnesota, United States
Calgary, Alberta, Canada
Beijing, China
Changsha, China
Chengdu, China
Guangzhou, China
Wuhan, China
Horsens, Denmark
Berlin, Germany
Lecce, Italy
Messina, Italy
Milan, Italy
Tokyo, Japan
Lisbon, Portugal
Porto, Portugal
A Coruña, Spain
Barcelona, Spain
Bilbao, Spain
El Palmar, Spain
Huelva, Spain
Las Palmas de Gran Canaria, Spain
Madrid, Spain
Majadahonda, Spain
Palma de Mallorca, Spain
Salamanca, Spain
Valencia, Spain
Södertälje, Sweden
Umeå, Sweden
London, United Kingdom